Ignite Creation Date:
2025-12-25 @ 12:38 AM
Ignite Modification Date:
2025-12-25 @ 10:48 PM
Study NCT ID:
NCT01578967
Status:
COMPLETED
Last Update Posted:
2021-12-07
First Post:
2012-04-13
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
LCCC 1115
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |